218 related articles for article (PubMed ID: 36826438)
1. Senescence and Immunotherapy: Redundant Immunomodulatory Pathways Promote Resistance.
Oesterreich S; Aird KM
Cancer Immunol Res; 2023 Apr; 11(4):401-404. PubMed ID: 36826438
[TBL] [Abstract][Full Text] [Related]
2. Cellular senescence and the tumour microenvironment.
Takasugi M; Yoshida Y; Ohtani N
Mol Oncol; 2022 Sep; 16(18):3333-3351. PubMed ID: 35674109
[TBL] [Abstract][Full Text] [Related]
3. Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications.
Zhao B; Wu B; Feng N; Zhang X; Zhang X; Wei Y; Zhang W
J Hematol Oncol; 2023 Mar; 16(1):28. PubMed ID: 36945046
[TBL] [Abstract][Full Text] [Related]
4. Overcoming the senescence-associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer.
Chambers CR; Ritchie S; Pereira BA; Timpson P
Mol Oncol; 2021 Dec; 15(12):3242-3255. PubMed ID: 34137158
[TBL] [Abstract][Full Text] [Related]
5. Reshaping of the tumor microenvironment by cellular senescence: An opportunity for senotherapies.
D'Ambrosio M; Gil J
Dev Cell; 2023 Jun; 58(12):1007-1021. PubMed ID: 37339603
[TBL] [Abstract][Full Text] [Related]
6. Senescence and the tumor-immune landscape: Implications for cancer immunotherapy.
Chibaya L; Snyder J; Ruscetti M
Semin Cancer Biol; 2022 Nov; 86(Pt 3):827-845. PubMed ID: 35143990
[TBL] [Abstract][Full Text] [Related]
7. Distinct phenotypes and 'bystander' effects of senescent tumour cells induced by docetaxel or immunomodulatory cytokines.
Sapega O; Mikyšková R; Bieblová J; Mrázková B; Hodný Z; Reiniš M
Int J Oncol; 2018 Nov; 53(5):1997-2009. PubMed ID: 30226595
[TBL] [Abstract][Full Text] [Related]
8. Effects of senescence on the tumour microenvironment and response to therapy.
Reynolds LE; Maallin S; Haston S; Martinez-Barbera JP; Hodivala-Dilke KM; Pedrosa AR
FEBS J; 2024 Jun; 291(11):2306-2319. PubMed ID: 37873605
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell senescence-induced macrophage CD73 expression is a critical metabolic immune checkpoint in the aging tumor microenvironment.
Deng Y; Chen Q; Yang X; Sun Y; Zhang B; Wei W; Deng S; Meng J; Hu Y; Wang Y; Zhang Z; Wen L; Huang F; Wan C; Yang K
Theranostics; 2024; 14(3):1224-1240. PubMed ID: 38323313
[No Abstract] [Full Text] [Related]
10. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
11. The impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy.
Zhang W; Zhang K; Shi J; Qiu H; Kan C; Ma Y; Hou N; Han F; Sun X
Aging Cell; 2024 May; 23(5):e14182. PubMed ID: 38650467
[TBL] [Abstract][Full Text] [Related]
12. The role of cellular senescence and SASP in tumour microenvironment.
Takasugi M; Yoshida Y; Hara E; Ohtani N
FEBS J; 2023 Mar; 290(5):1348-1361. PubMed ID: 35106956
[TBL] [Abstract][Full Text] [Related]
13. Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.
Sun X; Shi B; Zheng H; Min L; Yang J; Li X; Liao X; Huang W; Zhang M; Xu S; Zhu Z; Cui H; Liu X
Cell Death Dis; 2018 Feb; 9(3):260. PubMed ID: 29449532
[TBL] [Abstract][Full Text] [Related]
14. Chromatin basis of the senescence-associated secretory phenotype.
Hao X; Wang C; Zhang R
Trends Cell Biol; 2022 Jun; 32(6):513-526. PubMed ID: 35012849
[TBL] [Abstract][Full Text] [Related]
15. Senescent cells and SASP in cancer microenvironment: New approaches in cancer therapy.
Özdemir A; Şimay Demir YD; Yeşilyurt ZE; Ark M
Adv Protein Chem Struct Biol; 2023; 133():115-158. PubMed ID: 36707199
[TBL] [Abstract][Full Text] [Related]
16. Keeping the senescence secretome under control: Molecular reins on the senescence-associated secretory phenotype.
Malaquin N; Martinez A; Rodier F
Exp Gerontol; 2016 Sep; 82():39-49. PubMed ID: 27235851
[TBL] [Abstract][Full Text] [Related]
17. Assessing Functional Roles of the Senescence-Associated Secretory Phenotype (SASP).
Malaquin N; Tu V; Rodier F
Methods Mol Biol; 2019; 1896():45-55. PubMed ID: 30474839
[TBL] [Abstract][Full Text] [Related]
18. Mitofusin 1 silencing decreases the senescent associated secretory phenotype, promotes immune cell recruitment and delays melanoma tumor growth after chemotherapy.
Tarallo D; Martínez J; Leyva A; Mónaco A; Perroni C; Tassano M; Gambini JP; Cappetta M; Durán R; Moreno M; Quijano C
Sci Rep; 2024 Jan; 14(1):909. PubMed ID: 38195762
[TBL] [Abstract][Full Text] [Related]
19. Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy.
Liu X; Hoft DF; Peng G
J Clin Invest; 2020 Mar; 130(3):1073-1083. PubMed ID: 32118585
[TBL] [Abstract][Full Text] [Related]
20. Potential Regulators of the Senescence-Associated Secretory Phenotype During Senescence and Aging.
Han X; Lei Q; Xie J; Liu H; Li J; Zhang X; Zhang T; Gou X
J Gerontol A Biol Sci Med Sci; 2022 Nov; 77(11):2207-2218. PubMed ID: 35524726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
